SCHEMBL4240433

SCHEMBL4240433

CCCCCCCC(CC(C)=O)C(=O)OCC

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 2/20 0.50
CA2 P00918 2/20 0.46
ZDHHC7 Q9NXF8 1/20 0.43
GPR84 Q9NQS5 7/20 0.42
CA1 P00915 1/20 0.42
FAAH O00519 1/20 0.41
GRIK1 P39086 1/20 0.41
GRIK2 Q13002 1/20 0.41
FFAR1 O14842 1/20 0.40
BIRC2 Q13490 1/20 0.39
CES2 O00748 1/20 0.39
MAPT P10636 1/20 0.39
LCK P06239 1/20 0.39
PPARD Q03181 1/20 0.39
ZDHHC20 Q5W0Z9 1/20 0.39
ZDHHC2 Q9UIJ5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4552685 1.00 CPB2 (0.50) CPB2CA2ZDHHC7GPR84CA1
Oxalic Acid SCHEMBL10673743 0.95 CPB2 (0.46) CPB2CA2ZDHHC7GPR84CA1
SCHEMBL12577919 0.93 CA2 (0.48) CPB2CA2CA1BIRC2
SCHEMBL18531126 0.87 CPB2 (0.58) CPB2CA2ZDHHC7GPR84CA1
SCHEMBL19148651 0.87 CPB2 (0.58) CPB2CA2ZDHHC7GPR84CA1
SCHEMBL23879492 0.87 CPB2 (0.58) CPB2CA2ZDHHC7GPR84CA1
SCHEMBL5580131 0.87 CPB2 (0.58) CPB2CA2ZDHHC7GPR84CA1
SCHEMBL571313 0.87 CPB2 (0.58) CPB2CA2ZDHHC7GPR84CA1
SCHEMBL25341592 0.87 CPB2 (0.58) CPB2CA2ZDHHC7GPR84CA1
SCHEMBL5516547 0.87 CPB2 (0.58) CPB2CA2ZDHHC7GPR84CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3363796-B1 METHOD FOR PRODUCING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2021-04-07 EP disclosed
US-10829474-B2 Method for producing heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-11-10 US disclosed
US-20200172509-A1 METHOD FOR PRODUCING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-06-04 US disclosed
US-10562881-B2 Method for producing heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-02-18 US disclosed
US-20180297980-A1 METHOD FOR PRODUCING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-10-18 US disclosed
EP-3363796-A1 METHOD FOR PRODUCING HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2018-08-22 EP disclosed
US-20090093473-A1 Spiro-benzimidazoles as inhibitors of gastric acid secretion NYCOMED GMBH (DE) 2009-04-09 US disclosed
EP-1899338-A1 SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION Nycomed GmbH (DE) 2008-03-19 EP disclosed
WO-2006134111-A1 SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION NYCOMED GMBH (DE) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093473-A1 Spiro-benzimidazoles as inhibitors of gastric acid secretion GIPR, PGC, SLC10A2 CPB2 1224/4885CA2 99/4885ZDHHC7 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.